TEDA Welcomes Two Major Projects

Recently, at the 2023 Green Investment Industry Forum, the second phase of the Linggas R&D Industrialization Base and the core raw material R&D pilot-scale experiment project of Rianlon New Materials for nucleic acid drugs settled in TEDA.

Linggas positions its plant in Nangang as the group’s headquarters, research and development center, and main production base. It will undertake important functions such as the group’s IPO listing and the research and development of new products in the future. The first phase of the project is currently in operation. The total investment in the second phase of the Linggas R&D Industrialization Base project is approximately 235 million yuan. It will include an expanded production line of 710 tons/year of high-purity electronic gas materials for semiconductors. The products include six categories of electronic gas, and the trial production is planned for July 2025.

Rianlon Corporation will invest in Tianjin OliveBio Co., Ltd., to establish and operate a research and development pilot-scale experiment platform for core raw materials of nucleic acid drugs. This project is dedicated to the research and industrialization of products such as nucleosides, nucleotides and their derivatives, fluorescent probes, and gene sequencing materials.